Alterations in sarcoplasmic reticulum and mitochondrial functions in diabetic cardiomyopathy

Experimental and Clinical Cardiology

Volumn 17, Issue 3, 2012, Pages 115-120

  Dhalla, Naranjan S ^a   Rangi, Shashanka ^a   Zieroth, Shelley ^a   Xu, Yan Jun ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Diabetic cardiomyopathy; Mitochondria; Sarcoplasmic reticulum; Subcellular remodelling

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN II; CALCIUM CHANNEL L TYPE; CALCIUM ION; CALSEQUESTRIN; CASPASE 3; CATECHOLAMINE DERIVATIVE; CYTOCHROME C; ENDOTHELIN; FATTY ACID; GLUCOSE; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATASE; PHOSPHATIDYLINOSITOL; PHOSPHOLAMBAN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SODIUM CALCIUM EXCHANGE PROTEIN; TROPONIN C;

APOPTOSIS; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL DAMAGE; CELL FUNCTION; CELL MEMBRANE DEPOLARIZATION; DEPOLARIZATION; DIABETIC CARDIOMYOPATHY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON TRANSPORT; ENERGY YIELD; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART CONTRACTION; HEART MUSCLE CELL; HORMONE BLOOD LEVEL; HUMAN; INTRACELLULAR SIGNALING; LIPID TRANSPORT; METABOLIC DISORDER; MICROANGIOPATHY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SARCOPLASMIC RETICULUM; TRANSGENIC MOUSE; UPREGULATION;

EID: 84867466453     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. (Pubitemid 38579764)
2. Dhalla NS, Pierce GN, Innes IR, et al. Pathogenesis of cardiac dysfunction in diabetes mellitus. Can J Cardiol 1985;1:263-81. (Pubitemid 15236913)
3. Dhalla NS, Liu X, Panagia V, et al. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 1998;40:239-47. (Pubitemid 28506032)
4. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000;18:655-73. (Pubitemid 30406736)
5. Boudina S, Albel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115:3213-23. (Pubitemid 47012236)
6. Dhalla NS, Pierce GN, Panagia V, et al. Calcium movements in relation to heart function. Basic Res Cardiol 1982;77:117-39. (Pubitemid 12154431)
7. Müller AL, Dhalla NS. Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev 2012;17:395-409.
8. Zhang L, Kelley J, Schmeisser G, et al. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor proteins of the cardiac junctional sarcoplamic reticulum membrane. J Bio Chem 1997;272:23389-97. (Pubitemid 27392481)
9. Ganguly PK, Pierce GN, Dhalla KS, et al. Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol Endocrinol Metab 1983;244:E528-35. (Pubitemid 13067062)
10. Penpargkul S, Fein F, Sonnenblick EH, et al. Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol 1981;13:303-9. (Pubitemid 11155567)
11. Lopaschuk GD, Tahiliani AG, Vadlamudi RV, et al. Cardiac sarcoplasmic reticulum function in insulin- or carnitine-treated diabetic rats. Am J Physiol Heart Circ Physiol 1983;245:H969-76. (Pubitemid 14212751)
12. 2+ signalling contributes to cardiomyopathy in type 1 diabetic rats. Am J Physiol Heart Circ Physiol, 2002;283:H1398-408.
13. 2+ release in cardiomyocytes by angiotensin II receptor blockade. Am J Physiol Heart Circ Physiol 2007;292:H912-20.
14. 2+- transport in alloxan-induced diabetes in rats. Diabetes Res Clin Pract 1996;31:S73-7.
15. Schaffer SW, Mozaffari MS, Artman M, et al. Basis for myocardial mechanical defects associated with non-insulin dependent diabetes. Am J Physiol Endocrinol Metab 1989; 256:E25-30.
16. Schaffer SW. Cardiomyopathy associated with non-insulin dependent diabetes. Mol Cell Biochem 1991;107:1-20.
17. Yu Z, Tibbits GF, McNeill JH. Cellular functions of diabetic cardiomyocytes: Contractility, rapid cooling contracture and ryanodine binding. Am J Physiol Heart Circ Physiol 1994;266:H2082-9. (Pubitemid 24172151)
18. 2+ cycling proteins may underlie sarcoplamic reticulum dysfunction in the diabetic heart. Diabetes 2001;50:2133-8.
19. Zhong Y, Ahmed S, Grupp IL, et al. Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. Am J Physiol Heart Circ Physiol 2001;281:H1137-47.
20. Xu YJ, Elimban V, Takeda S, et al. Cardiac sarcoplasmic reticulum function and gene expression in chronic diabetes. Cardiovasc Pathobiol 1996;1:89-96.
21. Zhou BQ, Hu SJ, Wang GB. The analysis of ultrastructure and gene expression of sarco/endoplasmic reticulum calcium handling proteins in alloxan-induced diabetic rat myocardium. Acta Cardiol 2006;61:21-7.
22. 2+ ATPase expression in streptozotocin-induced diabetic rat heart. Biochem Biophys Res Commun 1994;203:113-20.
23. Golfman L, Dixon IM, Takeda N, et al. Differential changes in cardiac myofibrillar and sarcoplamic reticular gene expression in alloxan-induced diabetes. Mol Cell Biochem 1999;200:15-25. (Pubitemid 29490650)
24. Takeda N, Dixon IM, Hata T, et al. Sequence of alterations in subcellular organelles during the development of heart dysfunction in diabetes. Diabetes Res Clin Pract 1996;30:S113-22. (Pubitemid 26096593)
25. Vasanji Z, Dhalla NS, Netticadan T. Increased inhibition of SERCA2 by phospholamban in the type 1 diabetic heart. Mol Cell Biochem 2004;261:245-9. (Pubitemid 39004537)
26. Bidasee KR, Zhang Y, Shao CH, et al. Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+ ATPase. Diabetes 2004;53:463-73. (Pubitemid 38174564)
27. 2+-ATPase and myosin heavy chain isozyme switch. Diabetologia 2006;49:1434-46.
28. Bergh CH, Hjalmarson A, Sjogren KG, et al. The effect of diabetes on phosphatidylinositol turnover and calcium influx in myocardium. Horm Metab Res 1988;20:381-6.
29. Li Y, Li Y, Feng Q, et al. Calpain activation contributes to hyperglycemia-induced apoptosis in cardiomyocytes. Cardiovasc Res 2009;84:100-10.
30. Belke DD, Swanson EA, Dillman WH. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 2004;53:3201-8. (Pubitemid 39564496)
31. 2+-ATPase activity contributes to cardiac dysfunction in streptozotocin-induced diabetic rats. J Physiol Biochem 2006;62:1-8.
32. Suarez J, Scott B, Dillmann WH. Conditional increase in SERCA2a protein is able to reverse contractile dysfunction and abnormal calcium flux in established diabetic cardiomyopathy. Am J Physiol Regul Integr Comp Physiol 2008;295:R1439-45.
33. 2+)i isoproterenol and cAMP in isolated cardiomyocytes from experimental diabetic rats. Am J Physiol Heart Circ Physiol 1994;266:H2334-42.
34. 2+ homeostasis in rat heart. Diabetes 2005;54:3082-8.
35. 2+ concentration and pH of diabetic rat myocytes during metabolic inhibition. J Mol Cell Cardiol 1992;24:435-46.
36. 2+ handling in ventricular myocytes isolated from diabetic rats. Am J Physiol Heart Circ Physiol 1996;270:H1529-37.
37. 2+ transport, fatty acid, profiles and ultrastructure of isolated rat ventricular myocytes. Pflugers Arch 1988;411:564-72.
38. Dhalla NS, Wang X, Beamish RE. Intracellular calcium handling in normal and failing hearts. Exp Clin Cardiol 1996;1:7-20.
39. i transient in cardiomyopathy of db/db type 2 diabetic mice. Diabetes 2006;55:608-15.
40. 2+ pump activity during diabetes mellitus. Am J Physiol Heart Circ Physiol 1987;252:H540-4.
41. 2+ transport in streptozotocin-induced diabetic cardiomyopathy in rats. Am J Physiol Endocrinol Metab 1987;253:E202-7.
42. Sauviat MP, Feuvray D. Electrophysiological analysis of the sensitivity to calcium in ventricular muscle from alloxan diabetic rats. Basic Res Cardiol 1986;81:489-96. (Pubitemid 17168554)
43. Borda E, Pascual J, Wald M, et al. Hypersensitivity to calcium associated with an increased sarcolemmal Ca2+ ATPase activity in diabetic rat heart. Can J Cardiol 1988;4:97-101.
44. 2+ binding by and composition of the cardiac sarcolemmal membrane in chronic diabetes. Proc Natl Acad Sci USA 1983;80:5412-6.
45. + ATPase activity in diabetic rat heart. Am J Physiol Cell Physiol 1983;245:C241-7.
46. + pump concentration in skeletal muscles, heart ventricular muscle, and peripheral nerves of rat. Diabetes 1987;36:842-8.
47. + ATPase activities and gene expression in alloxan-induced diabetes in rats. Mol Cell Biochem 1998;188:91-101.
48. 2+ exchange. Can J Physiol Pharmacol 2000;78:7812-19.
49. 2+ overload. J Physiol 2000;527:85-94.
50. Lagadic-Gossmann D, Feuvray D. Intracellular sodium activity in papillary muscle from diabetic rat hearts. Exp Physiol 1991;76:147-9.
51. Nagase N, Saijo Y, Nitta H, et al. Myocardial disorders caused by magnesium deficiency in diabetic KK mice. Magnesium 1989;8:307-15. (Pubitemid 20038800)
52. Regan TJ, Wu CF, Yeh CK, et al. Myocardial composition and function in diabetes. The effects of chronic insulin use. Circ Res 1981;49:1268-77. (Pubitemid 12246596)
53. Afzal N, Pierce GN, Elimban V, et al. Influence of verapamil on some subcellular defects in diabetic cardiomyopathy. Am J Physiol Endocrinol Metab 1989;256: E453-8.
54. Afzal N, Ganguly PK, Dhalla KS, et al. Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 1988;37:936-42. (Pubitemid 19043725)
55. Liu X, Suzuki H, Sethi R, et al. Blockade of the renin-angiotensin system attenuates sarcolemma and sarcoplasmic reticulum remodeling in chronic diabetes. Ann N Y Acad Sci 2006;1084:141-54. (Pubitemid 47091938)
56. Dhalla NS, Das PK, Sharma GP. Subcellular basis of cardiac contractile failure. J Mol Cell Cardiol 1978;10:363-85. (Pubitemid 8315212)
57. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Phys Rev 2005;85:1093-129. (Pubitemid 40894649)
58. Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: Implications in diabetic cardiomyopathy. J Mol Cell Cardiol 1995;27:169-79.
59. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-9.
60. Mazumder PK, O'Neill BT, Roberts MW, et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004;53:2366-74. (Pubitemid 39145591)
61. Carley AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 2005;1734:112-126.
62. Herrero P, Peterson LR, McGill JB, et al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2006;47: 598-604. (Pubitemid 43170851)
63. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor alpha (PPARalpha) signalling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 2002;34:1249-57. (Pubitemid 35244398)
64. Banke NH, Wende AR, Leone TC, et al. Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPAR alpha. Circ Res 2010;107:233-41.
65. Duncan JG, Fong JL, Medeiros DM, et al. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator- activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 2007;115:909-17. (Pubitemid 46294731)
66. Kuo TH, Moore KH, Giacomelli F, et al. Defective oxidative metabolism of heart mitochondria from genetically diabetic mice. Diabetes 1983;32:781-7. (Pubitemid 13038892)
67. Pierce GN, Dhalla NS. Heart mitochondrial function in chronic experimental diabetes in rats. Can J Cardiol 1985;1:48-54. (Pubitemid 15239699)
68. Flarsheim CE, Grupp IL, Matlib MA. Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. Am J Physiol Heart Circ Physiol 1996; 271:H192-202.
69. Finck BN, Lehman JJ, Leone TC, et al. The cardiac phenotype induced by PPARalpha over expression mimics that caused by diabetes mellitus. J Clin Invest 2002;109:121-30. (Pubitemid 34052548)
70. Finck BN, Han X, Courtois M, et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content. Proc Natl Acad Sci USA 2003;100:1226-31. (Pubitemid 36183984)
71. Finck BN. The role of the peroxisome proliferator-activated receptor alpha pathway in pathological remodelling of the diabetic heart. Curr Opin Clin Nutr Metab Care 2004;7:391-6. (Pubitemid 40340644)
72. Cheng L, Ding G, Qin Q, et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004;10:1245-50. (Pubitemid 39540443)
73. Yagyu H, Chen G, Yokoyama M, et al. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 2003;111:419-26. (Pubitemid 36182219)
74. Listenberger LL, Ory DS, Schaffer JE. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem 2001;276:14890-5.
75. Ostrander DB, Sparagna GC, Amoscato AA, et al. Decreased cardiolipin synthesis corresponds with cytochrome C release in palmitate-induced cardiomyocyte apoptosis. J Biol Chem 2001;276:38061-7.
76. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 1999;48:1-9. (Pubitemid 29019345)
77. Giardino I, Fard AK, Hatchell DL, et al. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998;47:1114-20. (Pubitemid 28294555)
78. Ohuwa T, Sato Y, Naoi M. Hydroxyl radical formation in diabetic rats induced by streptozotocin. Life Sci 1995;56:1789-98.
79. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010;11:31-9.
80. Kowluru RA, Engerman RL, Kern TS. Diabetes-induced metabolic abnormalities in myocardium: Effect of antioxidant therapy. Free Radic Res 2000;32:67-74. (Pubitemid 30010609)
81. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223-34.
82. Taniguchi N, Kaneto H, Asahi M, et al. Involvement of glycation and oxidative stress in diabetic macroangiopathy. Diabetes 1996;45:S81-3.
83. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991;10:339-59.
84. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:788-91.
85. Peiro C, Lafuente N, Matesanz N, et al. High glucose induces cell death of cultured human aortic smooth muscle cells through the formation of hydrogen peroxide. Br J Pharmacol 2001;133:967-74. (Pubitemid 32762405)
86. Kajstura J, Fiordaliso F, Andreoli AM, et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 2001;50:1414-24. (Pubitemid 32500175)
87. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 2003;552:335-44. (Pubitemid 37321833)
88. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-90. (Pubitemid 30212409)
89. Boudina S, Bugger H, Sena S, et al. Contribution of impaired myocardial insulin signalling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009;119:1272-83.
90. Cai L, Li W, Wang G, et al. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002;51:1938-48. (Pubitemid 34564309)
91. Ghosh S, Pulinilkunnil T, Yuen G, et al. Cardiomyocyte apoptosis induced by short-term diabetes requires mitochondrial GSH depletion. Am J Physiol Heart Circ Physiol 2005;289:H768-76. (Pubitemid 41129394)
92. Shen X, Zheng S, Metreveli NS, et al. Protection of cardiac mitochondria by over expression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006;55:798-805. (Pubitemid 43343239)
93. Ye G, Metreveli NS, Donthi RV, et al. Catalase protects cardiomyocyte function in models of type 1 and type2 diabetes. Diabetes 2004;53:1336-43. (Pubitemid 38569021)
94. Cai L, Wang Y, Zhou G, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006;48:1688-97. (Pubitemid 44528172)
95. 2+ signalling. Physiology 2008;23:84-94.
96. 2+ permeable channels. FEBS Lett 2010;584:1948-55.
97. Duchen MR. Roles of mitochondria in health and disease. Diabetes 2004;53:S96-102.